366results about How to "Improve therapeutic index" patented technology

A method of treating a patient undergoing pharmacotherapy with a selected drug for treatment of a medical disorder is provided which comprises: (a) administering the selected drug to said patient at a first time point, to treat the medical disorder; and (b) applying an electrical signal to a vagus nerve of the patient at a second time point, wherein the signal is selected so as to modulate at least one pharmacologic and / or pharmacokinetic property of the selected drug in the body of the patient. The vagus nerve stimulation (VNS) modulated drug therapy may be performed secondarily to, and in conjunction with, application of a primary VNS therapy to the patient for treatment of the same or a different medical disorder, to enhance treatment of the patient.

New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.

The invention relates to a preparation method and application of 9-bit substituent double-functional group berberine derivatives. In-vitro biological activity assay research shows that the 9-bit substituent double-functional group berberine derivatives provided by the invention has acetylcholinesterase inhibition activity higher than that of berberine serving as a leading compound, and also has higher inhibition activity on butyrylcholine esterase. After being further optimized and screened, the derivatives have favorable foreground of being developed into medicaments for treating diseases such as AD disease, vascular dementia, cognitive dysfunction and the like. The general formula of the derivatives is shown as the following formula, wherein X, Y and Z are defined in specifications.

The invention relates to nanoliposome human papillomavirus (HPV) resistant and gynecological inflammation pathogen resistant specific complex IgY and a combined preparation for the same. Laying poultry is preferred to respectively prepare laying poultry for immunity of tumor somatic cells, viral protein complex antigens, gene recombination protein antigens and bacterial virus complex antigens; and human papillomavirus resistant special IgY and gynecological inflammation pathogen resistant specific IgY undergo affinity chromatography and purification and are converted into nanoliposomes, and then the nanoliposome special complex IgY is prepared. The nanoliposome human papillomavirus (HPV) resistant and gynecological inflammation pathogen resistant specific complex IgY and the combined preparation for the same have the advantages that: the nanoliposome technology is applied to increase the infiltration capacity and the prolongation effect and improve the curative effect. The nanoliposome human papillomavirus (HPV) resistant and gynecological inflammation pathogen resistant specific complex IgY and the combined preparation for the same can be prepared into various vaginal spraying agents, other spraying agents, lotion, gel, capsules, suppository, vaginal membranes, tablets, effervescent tablets, ointment, cream and so on. The nanoliposome complex IgY can infiltrate into a vagina mucosa to effectively remove HPV viruses and gynecological inflammation pathogens which are absorbed on the vaginal surface layer and in the vagina mucosa, is absorbed through the vagina mucosa and enters into the body to give play to the functions of prevention and treatment, and also can effectively prevent recrudescence.

Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents.

The invention provides a curcumenol solid lipid nanoparticle and its preparation method, which comprises curcumenol 1 part, phospholipids 3-10 parts, grease material 5-100 parts, surface active agent 10-200 parts and excipient 10-400 parts.

The invention discloses 6-cyclohexyl methyl substituted S-DABO type compound, the synthesis method and the application, belonging to the medical technical field. The invention relates to a 5-alkyl-6-cyclohexyl methyl-2-(alkyl, naphthenic base, naphthenic base methyl, substituted phenylethanone) thiouracil type compound, which has general formula as shown in (I): wherein, R1 is alkyl of C1-3; alkyl, naphthenic base and naphthenic base methyl of R2=C1-8 are as shown in (II); wherein, X=OCH3, H, OH, halogen. Chloromethyl cyclohexane or cyclohexyl acetic acid is respectively used as raw material to prepare Beta- keto ester which is made into a key intermediate 5-alkyl-6-cyclohexyl methyl thiouracil together with thiourea through close loop condensation under the catalyzing of sodium alkoxide; target molecule is prepared through S-alkylation guiding C2-side chain. The invention has the advantages of simple and easy synthesis method, obvious anti-HIV virus activity and anti-resistance for the drugs and ability to be used as an alternative for anti-HIV drug.

The present invention is (-)-meptazinol carbamate derivative as shown and / or its salt and their preparation process and use in preparing medicine for treating dementia including Alzheimer disease. The said compound, extracorporeal experiment shows, has very high AChE and BChE inhibiting activity, hundreds times higher than that of available medicine.

The invention relates to an edaravone lipid microsphere formulation and a preparation method thereof. The edaravone lipid microsphere formulation is prepared by taking the mixed emulsifier of granulesten and poloxamer188 with specific rate as an emulsifier and injection soybean oil as oil phase solvent, and also contains pharmaceutically regular antioxidant. Not only does the prepared edaravone lipid microsphere injection have simple process, low cost and easy industrial production, but also obviously improved stability compared with the existing edaravone injection.

The invention provides a Prasugrel liposome solid preparation, which is characterized by being prepared by the following main components in parts by weight: 1 part of Prasugrel, 2-18 parts of yolk phosphatidylglycerol, 0.6-9 parts of cholesterol, 1.2-12 parts of sodium glycyl-cholate and 4-80 parts of other pharmaceutically accepted excipients. The Prasugrel liposome prepared by the invention has high entrapment rate and little side effect, improves stability of aqueous solubility thereof greatly and is favor of dissolving medicinal preparation out.